Table 2.
List of current investigated IDO1 inhibitors. Information about the above trials can be accessed at https://www.clinicaltrials.gov/.
| IDO | Notes | Indications | Phase | Status | Mechanism | Reference |
|---|---|---|---|---|---|---|
| IDO peptides | Nivolumab and PD-L1/IDO peptide vaccine | Metastatic melanoma | Phase 1 Phase 2 |
Recruiting | Combination therapy with nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma | NCT03047928 |
| KHK2455 | Combined with avelumab | Urothelial carcinoma | Phase 1 | Recruiting | KHK2455 (IDO inhibitor) plus avelumab in adult subjects with advanced bladder cancer | NCT03915405 |
| Epacadostat | Combined with pembrolizumab | Sarcoma | Phase 2 | Active, not recruiting | A study of Epacadostat, an IDO1 inhibitor, in combination with pembrolizumab in patients with metastatic and/or locally advanced sarcoma | NCT03414229 |
| Indoximod | Combined with docetaxel | Non-small cell lung cancer Progression of non-small cell lung cancer Non-small cell lung cancer recurrent |
Phase 1 | Active, not recruiting | Immunotherapy combination study in advanced previously treated non-small cell lung cancer | NCT02460367 |
| Epacadostat (INCB 024360) | Combined with CDX-1401 and poly ICLC | Fallopian tube carcinoma Ovarian carcinoma Primary peritoneal carcinoma |
Phase 1 Phase 2 |
Active, not recruiting | DEC-205/NY-ESO-1 fusion protein CDX-1401, Poly ICLC, and IDO1 inhibitor INCB024360 in treating patients with ovarian, fallopian tube, or primary peritoneal cancer in remission | NCT02166905 |
| Linrodostat (BMS-986205) | Combined with nivolumab | Endometrial adenocarcinoma Endometrial carcinosarcoma | Phase 2 | Recruiting | Study of BMS-986205 and nivolumab in endometrial cancer or endometrial carcinosarcoma that has not responded to treatment | NCT04106414 |
| Celecoxib 200 mg capsule | As single agent | Endometrium cancer | Phase 2 | Recruiting | Neoadjuvant Celecoxib in newly diagnosed patients with endometrial carcinoma | NCT03896113 |
| Linrodostat (BMS-986205) | Combined with relatlimab and nivolumab | Advanced cancer | Phase 1 Phase 2 |
Recruiting | An investigational study of immunotherapy Combinations in participants with solid cancers that are advanced or have spread | NCT03459222 |
| Linrodostat (BMS-986205) | Combined with nivolumab and temozolomide | Glioblastoma | Phase 1 | Recruiting | Nivolumab, BMS-986205, and radiation therapy with or without temozolomide in treating patients with newly diagnosed glioblastoma | NCT04047706 |
| Epacadostat (INCB 024360) | Combined with pembrolizumab | Head and neck cancer | Phase 3 | Active, not recruiting | Pembrolizumab plus Epacadostat, pembrolizumab monotherapy, and the extremeregimen in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ ECHO-304) | NCT03358472 |
| Epacadostat (INCB 024360) | Combined with pembrolizumab | Renal cell carcinoma (RCC) | Phase 3 | Active, not recruiting | Pembrolizumab (MK-3475) plus Epacadostat vs. standard of care in mRCC (KEYNOTE-679/ ECHO-302) | NCT Number |
| Epacadostat (INCB 024360) | Combined with pembrolizumab | Metastatic pancreatic adenocarcinoma | Phase 2 | Recruiting | Epacadostat, pembrolizumab, and CRS-207, with or without CY/GVAX pancreas in patients with metastatic pancreas cancer | NCT03260894 |
| Indoximod | Combined with chemotherapy and radiation | Glioblastoma Medulloblastoma Ependymoma Diffuse intrinsic pontine glioma |
Phase 2 | Recruiting | Pediatric trial of Indoximod with chemotherapy and radiation for relapsed brain tumors or newly diagnosed diffuse intrinsic pontine glioma | NCT03006302 |